World's Definitive CAR-TCR EventWelcome to the 10th CAR-TCR Summit!
Hope is renewed for the cell therapy industry in 2025 fuelled by a 30% year on year increase in investment, notably in the cases of Arsenal Bio, Enara Bio and AvenCell. Landmark approvals for solid tumors from Adaptimmune and Iovance, along with significant clinical progress from Adicet Bio and Cartesian Therapeutics all signify huge strides forward for the industry. Don’t sit back and watch. Join the 10th Anniversary of the CAR-TCR Summit to reflect on a decade of progress whilst engaging in solutions-driven discussions that will empower you to tackle cell therapy development challenges to help shape the future of the field.
Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umjoa Biopharma, this meeting will equip you to overcome challenges across the entire development landscape - spanning durability, manufacturing timelines, potency assay matrix, solid tumor targeting, biomarker data, high cost of goods, scale up and scale out, and more, to make rapid advancements in the clinic and beyond. This is your definitive annual industry touchpoint to unlock breakthrough platform technology, accelerate clinical translation, and streamline manufacturing to deliver life changing cell therapies for patients in oncology and beyond.
Whether your focus is on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, or Analytical Development you can expect to gain in-depth insights across the entire cell therapy value chain.
Is industry collaboration your priority? Take part in 15+ hours of dedicated networking, from drinks receptions, poster sessions, and pharma partnering mixers. Maximize your opportunity to meet key industry stakeholders and expand your network.
Your Complete Guide to the Meeting is Here:
Key Highlights of the 10th CAR-TCR Summit:
Holistic Coverage of Cell Therapies Across Multiple Cell Types
51% CAR-Ts, 20% TCRs, 18% NK, Gamma Delta, Macrophages, TILs and Tregs, and 11% multiple cell types to give full visibility of advancements in cell therapy
Comprehensive Coverage of Indications
Spanning haem, and solid tumors, to autoimmune indications - understand the challenges when targeting different indications from cell engineering to patient recruitment nuances
Brand New Biotech & Pharma Partnering Day
Join some of the key players involved in recent mergers and acquisitions, including AstraZeneca, Johnson & Johnson, and Merck, to gain insider insights into the decision-making processes
6 Workshops & 3 Focus Days
Explore the future of potential of cell therapy with deep dives into solid tumors, automation, and the fundamentals of development and partnerships
Full Cell Therapy Landscape Coverage
No matter your focus, you can expect content dedicated to your stage of development, function or stage
Previously Attending Companies:
Expert Speakers Include:
Mark Cobbold
Senior Vice President, Cell Therapy & Immuno-oncology, Discovery, Oncology R&D
AstraZeneca
“I’m excited to join this year’s summit to exchange bold ideas, share first-in-human data on iNKT cell therapy, and explore how we can expand the reach of cell therapy to patients suffering from autoimmune diseases. It’s a critical moment for collaboration and scientific innovation as we move beyond oncology.”
MiNK Therapeutics, 2025 Speaker
Lead Partner
Expertise Partners
